Proliferating cell nuclear antigen (PCNA) plays an essential role in DNA replication and repair. Tumor cells express high levels of PCNA, identifying it as a potentially ideal target for cancer therapy. Previously, we identified nine compounds termed PCNA inhibitors (PCNA-Is) that bind directly to PCNA, stabilize PCNA trimer structure, reduce chromatin-associated PCNA, and selectively inhibit tumor cell growth. Of these compounds, PCNA-I1 is most potent.
The purposes of this study were to further investigate the effects of targeting PCNA chromatin association on DNA damage and cytotoxicity and to evaluate the therapeutic potential of PCNA-I1 against tumors in mice. Given the important roles of tumor suppressor p53 in regulating sensitivity of tumor cells to chemotherapeutics, we performed studies in two human prostate cancer cell lines differing in p53 expression: LNCaP cells (wildtype p53) and PC-3 cells (p53-null). PCNA-I1 induced DNA damage and apoptosis in both LNCaP and PC-3 cells and enhanced DNA damage and apoptosis triggered by cisplatin. PCNA-I1 also induced autophagy in PC-3 cells. A short-term pretreatment with PCNA-I1 reduced colony formation by 50% in both cell lines. These data suggest that, unlike many other cytotoxic drugs, the effects of PCNA-I1 on tumor cells do not depend on expression of p53. Intravenous administrations of PCNA-I1 significantly retarded growth of LNCaP tumors of in nude mice without causing detectable effects on mouse body weight and hematology profiles. These data provide proof of concept that targeting PCNA chromatin association could be a novel and effective therapeutic approach for treatment of cancer.
Introduction
Prostate cancer continues to be the most frequently occurring cancer in men in the United States and the second leading cause of cancer related deaths in men (1) . While the 5 year survival rate of patients with localized prostate cancer is 100%, the prognosis for the10-20% of patients who develop castration-resistant prostate cancer (CRPC) within that 5 year follow-up window is poor (1, 2) . Currently, there is no cure for CRPC with treatment options limited to palliative care. Thus, indicating an urgent need for new and improved treatment modalities.
Proliferating cell nuclear antigen (PCNA) is a ubiquitous nuclear protein that plays an essential role in DNA replication and repair by providing replicative DNA polymerases and other partner proteins with the high processivity required to duplicate the entire genome (3-7).
As a member of the DNA sliding clamp family, functional PCNA is a ring-shaped homotrimer which is loaded onto chromatin by replication factor C (RFC) (8) (9) (10) . This allows PCNA to encircle and slide along DNA, increasing the efficiency of replicative DNA polymerases δ and ε during leading and lagging strand synthesis (7, 11) . Additionally, PCNA functions as a scaffold protein, binding a multitude of protein partners involved in many vital cellular processes such as DNA repair and cell cycle control (7, 12) . Collectively, these many functions of PCNA and its localization at the replisome put PCNA in a central position for determining the fate of the replication fork and numerous other cell signaling pathways.
Functional human PCNA are homotrimers joined in a head-to-tail arrangement (13, 14) .
Each PCNA monomer is comprised of 261 amino acids and contains two globular domains, providing the trimeric ring sixfold symmetry (15) . The toroid structure of PCNA is evolutionally nanomolar range (30) . Of those nine compounds PCNA-I1 was most potent. In this study, we show that treatment with PCNA-I1 induces DNA damage and programmed cell death and reduces clonogenicity of human prostate tumor cells. Furthermore, treatment with PCNA-I1 inhibited growth of LNCaP tumors in a xenograft model, providing proof of concept that targeting PCNA association with chromatin could be a novel and effective therapeutic approach for the treatment of cancer.
Materials and Methods
Mice. Specific pathogen-free male athymic nude mice were purchased from Jackson Laboratory (Bar Harbor, ME) and used in the study when they were 8-10 weeks of age. The mice were maintained in a Reagents. Crystal violet, protease inhibitor cocktail, propidium iodide, and cisplatin were purchased from Sigma Aldrich (St. Louis, MO). Antibodies against pChk2 (T68), p53, phosphor-p53 (S15), PCNA, cleaved PARP, and LC3B were purchased from Cell Signaling Technologies (Danvers, MA). Antibody to H2AX (S139) was purchased from Epitomics (Burlingame, CA). Bcl-2 antibody was purchased from Santa Cruz (Dallas, TX). Alexa Flour secondary antibodies were purchased from Invitrogen (Grand Island, NY). Hematology profile analysis. The whole blood was collected from the submandibular vein of mice for hematology profile analysis. Briefly, animals were held by the scruff and a needle was used to puncture the vein. Blood (4 mice per group) was collected in microtainer tubes with EDTA. Samples were analyzed the same day using a Hemavet 950FS (Drew Scientific, Waterbury, CT). Data is represented as mean ± SD.
Statistical Analysis. Data from each assay were expressed as means ± SD. Statistical differences between 2 groups were determined by the Student's t test. P < 0.05 was considered significantly different. 
Results

Treatment with PCNA-I1 activates the DNA damage response in prostate cancer
Previously, we showed that treatment with PCNA-I1 reduced PCNA association with chromatin, inhibited cell growth and BrdU incorporation in cells, and induced S and G2/M arrest (30) . Since PCNA is required for DNA synthesis and repair, the attenuation of PCNA association to chromatin by PCNA-I1 may result in prolonged stalling of replication forks and cause collapse of the replication machinery, potentially leading to DNA damage and programmed cell death (7).
As shown in Figure 1A Figure 1D ).
PCNA-I1 treatment induces programmed cell death in prostate tumor cells
Given the DNA damaged inflicted by treatment with PCNA-I1, we analyzed the effects of PCNA-I1 on apoptosis by using Annexin V staining and flow cytometry (Figure 2A ). 
PCNA-I1 treatment induces autophagy in PC-3 cells
We next determined whether treatment with PCNA-I1 induced autophagy, the type-II programmed cell death. The phosphatidylethanolamine conjugated form of LC3B-I, known as LC3B-II, is commonly used as an autophagosomal marker. Immunofluorescent staining was used to visualize the LC3B puncta, an indicator of autophagasome formation, in LNCaP and PC-3 cells. LC3B puncta were present in both control and PCNA-I1-treated LNCaP cells, however, there was no statistical difference in the number of puncta per cell ( Figure 3A and B) . In 
contrast, there was a significant increase in the number of LC3B puncta present in PC-3 cells treated with PCNA-I1 ( Figure 3A and B) . The differential expression of LC3B in LNCaP and PC-3 cells was further determined using immunoblotting. While an increase in LC3B-I was observed in LNCaP cells treated with PCNA-I1, there was no expression of LC3B-II ( Figure   3C ). In contrast, treatment with PCNA-I1 increased the expression of LC3B-II at all time points in PC-3 cells ( Figure 3C ). Together, these data indicate that treatment with PCNA-I1 induced autophagy in PC-3 but not LNCaP cells.
Treatment with PCNA-I1 decreases clonogenicity of prostate tumor cells
Given that PCNA-I1 induced DNA damage and apoptosis in both LNCaP and PC-3 cells, and autophagy in PC-3 cells, we assessed the cytotoxic effects of a short-term (8 hours) PCNA-I1 exposure in a colony formation assay (31) . The untreated PC-3 cells formed 247 ± 28 colonies, which is approximately 2 times more than those formed by LNCaP cells (109 ± 25) ( Figure 4A and B) . The colonies formed by PC-3 cells were also significantly larger than those formed by LNCaP cells ( Figure 4A ). Despite differences in colony formation efficiencies between the two cell lines, the short-term treatment with PCNA-I1 resulted in approximately a 50% reduction in the colony formation by both LNCaP and PC-3 cells ( Figure 4C ). The treatment with PCNA-I1 also significantly reduced the sizes of the colonies ( Figure 4A ). These data indicated that a short-term pretreatment of PCNA-I1 was sufficient to produce the cytotoxic effects on LNCaP and PC-3 cells.
Intravenous injection of PCNA-I1 inhibits prostate tumor growth in vivo
One week after inoculation of LNCaP cells, tumor-bearing mice were intravenously Figure 5C ). To further evaluate potential acute (2 weeks after therapy intervention) systemic toxic effects of PCNA-I1, we examined the hematology profiles and found that the treatment of PCNA-I1 did not cause significant alterations to the profiles of leukocytes, erythrocytes, and thrombocytes (Table 1 ). These data indicate that the therapy with PCNA-I1 was effective against growth of LNCaP tumors and did not cause significant toxicity to the host.
Immunohistochemical analysis of tumor lesions showed that treatment with PCNA-I1 reduced expression of PCNA by approximately 26% (p<0.01, Figure 5D and E) and increased the number of apoptotic cells (TUNEL staining) by approximately 5 Fold (p<0.01, Figure 5D and F), respectively.
Discussion
Previously we reported a series of novel small molecule compounds which bind directly to PCNA trimers, stabilize the trimer structure, reduce PCNA association with chromatin, inhibit DNA replication, and selectively inhibit tumor cell growth (30) . In the present study, PCNA-I1, which is most potent among the nine PCNA-Is, was chosen for further investigation to determine the effects of targeting PCNA chromatin association on DNA damage and cytotoxicity and to evaluate therapeutic potential in a xenograft model of human prostate cancer in nude mice. protein, not detectable in normal human prostatic tissue, is expressed in primary prostatic adenocarcinoma and is further elevated in CRPC (38) . This expression of Bcl-2 has been shown to confer resistance to apoptotic stimuli both in vitro and in vivo and allow the normally androgen-sensitive LNCaP cells to form tumors in an androgen-depleted host, thus promoting progression of prostate cancer to CRPC (38, 39) . Therefore, the observed decrease in Bcl-2 expression upon treatment with PCNA-I1 suggests these cells may be sensitized to apoptosis. This finding is further confirmed by the fact that PCNA-I1 treatment sensitizes LNCaP cells to cisplatin treatment. Typically, prostate cancer is intrinsically resistant to cisplatin-based therapies (40) . However combination treatment of PCNA-I1 and cisplatin synergistically increased γH2AX, phospho-p53, and cleaved PARP expression and the percentage of apoptotic cells compared to cisplatin treatment alone. Similar findings of improved sensitivity to cisplatin via inhibition of translesion synthesis (TLS) using a small molecule inhibitor of PCNA that binds to the PIP-BOX have been reported (35, 36) . Whether PCNA-I1 improves sensitivity to cisplatin treatment through inhibition of TLS remains to be determined. The tumor suppressor protein p53, often mutated in human tumors, regulates apoptosis and cell survival upon DNA damage (40) (41) (42) (43) . Tumor cells with p53 mutations are often resistant to cytotoxic drugs, such as cisplatin (44) (45) (46) . Given that PC-3 cells do not express tumor suppressor p53, our data indicate that the cytotoxic effects of PCNA-I1 were likely mediated by both p53-dependent and -independent pathways. Autophagy, the type-II programmed cell death, has been described as having both cytoprotective and cytotoxic functions in tumor cells, both of which have implications for the treatment of cancer (47) . While autophagy is traditionally thought of as a cell-survival pathway, it has been demonstrated that excessive or prolonged autophagy results in "autophagic death" that occurs either independent of or in conjunction with apoptosis (48) (49) (50) . We examined the 
induces the cytotoxic form of autophagy. However, future studies using a pharmacologic inhibitor of autophagy such as bafilomycin, chloroquine, or 3-methyl adenine will be necessary to confirm PCNA-I1 induction of autophagic death. If in fact autophagy is playing a cytoprotective role in PC-3 cells, these inhibitors could be used to improve sensitivity to PCNA-I1 and promote apoptosis. Regardless of the mechanism of programmed cell death, the cytotoxic effects of PCNA-I1 on both LNCaP and PC-3 cells were further confirmed by data from the clonogenic assay. One of the important toxic side effects of many chemotherapeutic agents is depression of bone marrow, leading to leukopenia and thrombocytopenia, which may subsequently cause severe infection and septicemia. We found that the therapeutic dose of PCNA-I1 did not significantly change the body weights and hematology profiles of tumor-bearing mice, indicating that the treatment did not cause significant systemic toxicity. This is possibly due to the fact that (30) . Therefore, future studies will focus on further characterizing the effects of this class of compounds on the myriad of PCNA functions that could potentially be exploited for the treatment of a variety of cancers. PC-3 cells were seeded into a 6 well plate and allowed to adhere overnight before treatment with 1 μM PCNA-I1 for 8 hours. Cells were allowed to grow into colonies for 10 days before being fixed and stained with crystal violet. B, the number of colonies containing ≥ 50 cells was counted using a stereomicroscope. C, the surviving fraction was calculated using the formula, Surviving Fraction = (plating efficiency of treated/plating efficiency of control) x 100. *, p < 0.05, **, p < 0.01. 
